Cara Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Tvardi Therapeutics

03/03/2023 21:53

* Cara Therapeutics Inc  CARA.OQ   CARA.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 6. 
    * The Stamford Connecticut-based  company is expected to
report  a
1,879.4% increase in revenue to $16.251 million from $821
thousand a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cara Therapeutics
Inc is
for a loss of 32 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cara
Therapeutics
Inc is $25​, above​ its last closing price of $9.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.43       -0.42      -0.43     Missed  -2.7
 Jun. 30 2022  -0.25       -0.25      -0.08     Beat    68.4
 Mar. 31 2022  -0.54       -0.54      -0.52     Beat    3.1​
 Dec. 31 2021  -0.50       -0.52      -0.63     Missed  -22.2
 ​​Sep.        -0.35       -0.40      -0.02     Beat    94.9
 30 2021                                                
 Jun. 30 2021  -0.50       -0.53      -0.61     Missed  -14.5​
 Mar. 31 2021  -0.65       -0.59      -0.47     Beat    20.3
 Dec. 31 2020  0.37        0.36       1.59      Beat    336.5
 This summary was machine generated March 3 at 21:53 GMT.  All
figures in US dollars  unless otherwise stated